Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Frequent and Rare HABP2 Variants Are Not Associated with Increased Susceptibility to Familial Nonmedullary Thyroid Carcinoma in the Spanish Population.

de Randamie R, Martos-Moreno GÁ, Lumbreras C, Chueca M, Donnay S, Luque M, Regojo RM, Mendiola M, Hardisson D, Argente J, Moreno JC.

Horm Res Paediatr. 2018 Jun 12:1-11. doi: 10.1159/000487395. [Epub ahead of print]

PMID:
29895015
2.

The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance.

Fernández LP, Sánchez-Martínez R, Vargas T, Herranz J, Martín-Hernández R, Mendiola M, Hardisson D, Reglero G, Feliu J, Redondo A, Ramírez de Molina A.

Sci Rep. 2018 May 31;8(1):8485. doi: 10.1038/s41598-018-26468-4.

3.

High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease.

Heredia-Soto V, Redondo A, Berjón A, Miguel-Martín M, Díaz E, Crespo R, Hernández A, Yébenes L, Gallego A, Feliu J, Hardisson D, Mendiola M.

Oncotarget. 2018 Apr 24;9(31):21893-21903. doi: 10.18632/oncotarget.25098. eCollection 2018 Apr 24.

4.

Rapid Electrochemical Assessment of Tumor Suppressor Gene Methylations in Raw Human Serum and Tumor Cells and Tissues Using Immunomagnetic Beads and Selective DNA Hybridization.

Povedano E, Valverde A, Montiel VR, Pedrero M, Yáñez-Sedeño P, Barderas R, San Segundo-Acosta P, Peláez-García A, Mendiola M, Hardisson D, Campuzano S, Pingarrón JM.

Angew Chem Int Ed Engl. 2018 Jul 2;57(27):8194-8198. doi: 10.1002/anie.201804339. Epub 2018 Jun 6.

PMID:
29744991
5.

E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium.

Horne HN, Oh H, Sherman ME, Palakal M, Hewitt SM, Schmidt MK, Milne RL, Hardisson D, Benitez J, Blomqvist C, Bolla MK, Brenner H, Chang-Claude J, Cora R, Couch FJ, Cuk K, Devilee P, Easton DF, Eccles DM, Eilber U, Hartikainen JM, Heikkilä P, Holleczek B, Hooning MJ, Jones M, Keeman R, Mannermaa A, Martens JWM, Muranen TA, Nevanlinna H, Olson JE, Orr N, Perez JIA, Pharoah PDP, Ruddy KJ, Saum KU, Schoemaker MJ, Seynaeve C, Sironen R, Smit VTHBM, Swerdlow AJ, Tengström M, Thomas AS, Timmermans AM, Tollenaar RAEM, Troester MA, van Asperen CJ, van Deurzen CHM, Van Leeuwen FF, Van't Veer LJ, García-Closas M, Figueroa JD.

Sci Rep. 2018 Apr 26;8(1):6574. doi: 10.1038/s41598-018-23733-4.

6.

Electrochemical affinity biosensors for fast detection of gene-specific methylations with no need for bisulfite and amplification treatments.

Povedano E, Vargas E, Montiel VR, Torrente-Rodríguez RM, Pedrero M, Barderas R, Segundo-Acosta PS, Peláez-García A, Mendiola M, Hardisson D, Campuzano S, Pingarrón JM.

Sci Rep. 2018 Apr 23;8(1):6418. doi: 10.1038/s41598-018-24902-1.

7.

[Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].

Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.

Rev Esp Patol. 2018 Apr - Jun;51(2):84-96. doi: 10.1016/j.patol.2017.11.002. Epub 2018 Jan 17. Spanish.

PMID:
29602379
8.

Intratumoral activating GNAS (R201C) mutation in two unrelated patients with virilizing ovarian Leydig cell tumors.

Bieler BM, Gerber SM, Pérez de Nanclares G, Hardisson D, Lecumberri B.

Endocrinol Diabetes Nutr. 2017 Jun - Jul;64(6):335-337. doi: 10.1016/j.endinu.2017.03.007. Epub 2017 May 11. English, Spanish. No abstract available.

PMID:
29056280
9.

Erratum to: Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.

Clin Transl Oncol. 2018 Mar;20(3):424. doi: 10.1007/s12094-017-1746-7. No abstract available.

PMID:
28933007
10.

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer.

Peláez-García A, Yébenes L, Berjón A, Angulo A, Zamora P, Sánchez-Méndez JI, Espinosa E, Redondo A, Heredia-Soto V, Mendiola M, Feliú J, Hardisson D.

PLoS One. 2017 Sep 8;12(9):e0183452. doi: 10.1371/journal.pone.0183452. eCollection 2017.

11.

Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.

Clin Transl Oncol. 2018 Mar;20(3):274-285. doi: 10.1007/s12094-017-1719-x. Epub 2017 Aug 16. Erratum in: Clin Transl Oncol. 2017 Sep 20;:.

PMID:
28815456
12.

Subclassification of the molecular types of breast cancer based on the expression of immunohistochemical markers and evolution.

Reigosa A, Hardisson D, Sanzi F, Caleiras E, Saldivia F, Fernández A.

Invest Clin. 2016 Jun;57(2):187-216.

PMID:
28429898
13.

Primary Leiomyosarcoma of the Ovarian Vein: Case Report and Literature Review.

López-Ruiz ME, Yébenes L, Berjón A, Hardisson D.

Int J Surg Pathol. 2017 Jun;25(4):339-343. doi: 10.1177/1066896916679888. Epub 2016 Nov 23. Review.

PMID:
27881610
14.

Role of placental barrier integrity in infection by Trypanosoma cruzi.

Díaz-Luján C, Triquell MF, Castillo C, Hardisson D, Kemmerling U, Fretes RE.

Acta Trop. 2016 Dec;164:360-368. doi: 10.1016/j.actatropica.2016.09.021. Epub 2016 Sep 26.

PMID:
27686961
15.

G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis.

Nogués L, Reglero C, Rivas V, Salcedo A, Lafarga V, Neves M, Ramos P, Mendiola M, Berjón A, Stamatakis K, Zhou XZ, Lu KP, Hardisson D, Mayor F Jr, Penela P.

EBioMedicine. 2016 Nov;13:132-145. doi: 10.1016/j.ebiom.2016.09.030. Epub 2016 Oct 1.

16.

One-step nucleic acid amplification (OSNA) for the detection of sentinel lymph node metastasis in endometrial cancer.

López-Ruiz ME, Diestro MD, Yébenes L, Berjón A, Díaz de la Noval B, Mendiola M, De Santiago J, Hardisson D.

Gynecol Oncol. 2016 Oct;143(1):54-59. doi: 10.1016/j.ygyno.2016.07.106. Epub 2016 Aug 3.

PMID:
27498395
17.

Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel.

Mendiola M, Martínez-Marin V, Herranz J, Heredia V, Yébenes L, Zamora P, Castelo B, Pinto Á, Miguel M, Díaz E, Gámez A, Fresno JÁ, Ramírez de Molina A, Hardisson D, Espinosa E, Redondo A.

Oncotarget. 2016 Apr 26;7(17):24217-27. doi: 10.18632/oncotarget.8128.

18.

The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.

Gayarre J, Kamieniak MM, Cazorla-Jiménez A, Muñoz-Repeto I, Borrego S, García-Donas J, Hernando S, Robles-Díaz L, García-Bueno JM, Ramón Y Cajal T, Hernández-Agudo E, Heredia Soto V, Márquez-Rodas I, Echarri MJ, Lacambra-Calvet C, Sáez R, Cusidó M, Redondo A, Paz-Ares L, Hardisson D, Mendiola M, Palacios J, Benítez J, García MJ.

J Gynecol Oncol. 2016 Jan;27(1):e7. doi: 10.3802/jgo.2016.27.e7. Epub 2015 Nov 27.

19.

[Cadherins E and P expression in the molecular types of breast cancer].

Fernández Á, Reigosa A, Caleiras E, Saldivia F, Hardisson D, Sanz F.

Invest Clin. 2015 Jun;56(2):155-68. Spanish.

PMID:
26299056
20.

Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer.

Redondo A, Martínez V, Zamora P, Castelo B, Pinto A, Cruz P, Higuera O, Mendiola M, Hardisson D, Espinosa E.

Onco Targets Ther. 2014 Nov 27;7:2175-81. doi: 10.2147/OTT.S70654. eCollection 2014.

21.

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.

Conde E, Suárez-Gauthier A, Benito A, Garrido P, García-Campelo R, Biscuola M, Paz-Ares L, Hardisson D, de Castro J, Camacho MC, Rodriguez-Abreu D, Abdulkader I, Ramirez J, Reguart N, Salido M, Pijuán L, Arriola E, Sanz J, Folgueras V, Villanueva N, Gómez-Román J, Hidalgo M, López-Ríos F.

PLoS One. 2014 Sep 23;9(9):e107200. doi: 10.1371/journal.pone.0107200. eCollection 2014.

22.

Nomogram including the total tumoral load in the sentinel nodes assessed by one-step nucleic acid amplification as a new factor for predicting nonsentinel lymph node metastasis in breast cancer patients.

Rubio IT, Espinosa-Bravo M, Rodrigo M, Amparo Viguri Diaz M, Hardisson D, Sagasta A, Dueñas B, Peg V.

Breast Cancer Res Treat. 2014 Sep;147(2):371-80. doi: 10.1007/s10549-014-3108-2. Epub 2014 Aug 28.

PMID:
25164972
23.

Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium.

Milne RL, Burwinkel B, Michailidou K, Arias-Perez JI, Zamora MP, Menéndez-Rodríguez P, Hardisson D, Mendiola M, González-Neira A, Pita G, Alonso MR, Dennis J, Wang Q, Bolla MK, Swerdlow A, Ashworth A, Orr N, Schoemaker M, Ko YD, Brauch H, Hamann U; GENICA Network, Andrulis IL, Knight JA, Glendon G, Tchatchou S; kConFab Investigators; Australian Ovarian Cancer Study Group, Matsuo K, Ito H, Iwata H, Tajima K, Li J, Brand JS, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Lambrechts D, Peuteman G, Christiaens MR, Smeets A, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Hartman M, Hui M, Yen Lim W, Wan Chan C, Marme F, Yang R, Bugert P, Lindblom A, Margolin S, García-Closas M, Chanock SJ, Lissowska J, Figueroa JD, Bojesen SE, Nordestgaard BG, Flyger H, Hooning MJ, Kriege M, van den Ouweland AM, Koppert LB, Fletcher O, Johnson N, dos-Santos-Silva I, Peto J, Zheng W, Deming-Halverson S, Shrubsole MJ, Long J, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Cox A, Cross SS, Reed MW, Schmidt MK, Broeks A, Cornelissen S, Braaf L, Kang D, Choi JY, Park SK, Noh DY, Simard J, Dumont M, Goldberg MS, Labrèche F, Fasching PA, Hein A, Ekici AB, Beckmann MW, Radice P, Peterlongo P, Azzollini J, Barile M, Sawyer E, Tomlinson I, Kerin M, Miller N, Hopper JL, Schmidt DF, Makalic E, Southey MC, Hwang Teo S, Har Yip C, Sivanandan K, Tay WT, Shen CY, Hsiung CN, Yu JC, Hou MF, Guénel P, Truong T, Sanchez M, Mulot C, Blot W, Cai Q, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Bogdanova N, Dörk T, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Shu XO, Lu W, Gao YT, Zhang B, Couch FJ, Toland AE; TNBCC, Yannoukakos D, Sangrajrang S, McKay J, Wang X, Olson JE, Vachon C, Purrington K, Severi G, Baglietto L, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Devilee P, Tollenaar RA, Seynaeve C, Czene K, Eriksson M, Humphreys K, Darabi H, Ahmed S, Shah M, Pharoah PD, Hall P, Giles GG, Benítez J, Dunning AM, Chenevix-Trench G, Easton DF.

Hum Mol Genet. 2014 Nov 15;23(22):6096-111. doi: 10.1093/hmg/ddu311. Epub 2014 Jun 18.

24.

The PTEN/NRF2 axis promotes human carcinogenesis.

Rojo AI, Rada P, Mendiola M, Ortega-Molina A, Wojdyla K, Rogowska-Wrzesinska A, Hardisson D, Serrano M, Cuadrado A.

Antioxid Redox Signal. 2014 Dec 20;21(18):2498-514. doi: 10.1089/ars.2014.5843. Epub 2014 Jul 31.

25.

NIS mediates iodide uptake in the female reproductive tract and is a poor prognostic factor in ovarian cancer.

Riesco-Eizaguirre G, Leoni SG, Mendiola M, Estevez-Cebrero MA, Gallego MI, Redondo A, Hardisson D, Santisteban P, De la Vieja A.

J Clin Endocrinol Metab. 2014 Jul;99(7):E1199-208. doi: 10.1210/jc.2013-4249. Epub 2014 Apr 7.

PMID:
24708099
26.

FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium.

Agarwal D, Pineda S, Michailidou K, Herranz J, Pita G, Moreno LT, Alonso MR, Dennis J, Wang Q, Bolla MK, Meyer KB, Menéndez-Rodríguez P, Hardisson D, Mendiola M, González-Neira A, Lindblom A, Margolin S, Swerdlow A, Ashworth A, Orr N, Jones M, Matsuo K, Ito H, Iwata H, Kondo N; kConFab Investigators; Australian Ovarian Cancer Study Group, Hartman M, Hui M, Lim WY, Iau PT, Sawyer E, Tomlinson I, Kerin M, Miller N, Kang D, Choi J-, Park SK, Noh D-, Hopper JL, Schmidt DF, Makalic E, Southey MC, Teo SH, Yip CH, Sivanandan K, Tay W-, Brauch H, Brüning T, Hamann U; GENICA Network, Dunning AM, Shah M, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Schmidt MK, Broeks A, Rosenberg EH, van't Veer LJ, Fasching PA, Renner SP, Ekici AB, Beckmann MW, Shen C-, Hsiung C-, Yu J-, Hou M-, Blot W, Cai Q, Wu AH, Tseng C-, Van Den Berg D, Stram DO, Cox A, Brock IW, Reed MW, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Zheng W, Deming-Halverson S, Shrubsole MJ, Long J, Shu X-, Lu W, Gao Y-, Zhang B, Radice P, Peterlongo P, Manoukian S, Mariette F, Sangrajrang S, McKay J, Couch FJ, Toland AE; TNBCC, Yannoukakos D, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Marme F, Burwinkel B, Guénel P, Truong T, Sanchez M, Mulot C, Bojesen SE, Nordestgaard BG, Flyer H, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Mannermaa A, Kataja V, Kosma V-, Hartikainen JM, Lambrechts D, Yesilyurt BT, Floris G, Leunen K, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Wang X, Olson JE, Vachon C, Purrington K, Giles GG, Severi G, Baglietto L, Haiman CA, Henderson BE, Schumacher F, Marchand LL, Simard J, Dumont M, Goldberg MS, Labréche F, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Devilee P, Tollenaar RA, Seynaeve C, García-Closas M, Chanock SJ, Lissowska J, Figueroa JD, Czene K, Eriksson M, Humphreys K, Darabi H, Hooning MJ, Kriege M, Collée JM, Tilanus-Linthorst M, Li J, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova N, Dörk T, Hall P, Chenevix-Trench G, Easton DF, Pharroah PD, Arias-Perez JI, Zamora P, Benítez J, Milne RL.

Br J Cancer. 2014 Feb 18;110(4):1088-100. doi: 10.1038/bjc.2013.769.

27.

Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.

Natrajan R, Wilkerson PM, Marchiò C, Piscuoglio S, Ng CK, Wai P, Lambros MB, Samartzis EP, Dedes KJ, Frankum J, Bajrami I, Kopec A, Mackay A, A'hern R, Fenwick K, Kozarewa I, Hakas J, Mitsopoulos C, Hardisson D, Lord CJ, Kumar-Sinha C, Ashworth A, Weigelt B, Sapino A, Chinnaiyan AM, Maher CA, Reis-Filho JS.

J Pathol. 2014 Apr;232(5):553-65. doi: 10.1002/path.4325. Epub 2014 Feb 5.

28.

Developmental and tumoral vascularization is regulated by G protein-coupled receptor kinase 2.

Rivas V, Carmona R, Muñoz-Chápuli R, Mendiola M, Nogués L, Reglero C, Miguel-Martín M, García-Escudero R, Dorn GW 2nd, Hardisson D, Mayor F Jr, Penela P.

J Clin Invest. 2013 Nov;123(11):4714-30. doi: 10.1172/JCI67333. Epub 2013 Oct 25.

29.

Reproducibility of current classifications of endometrial endometrioid glandular proliferations: further evidence supporting a simplified classification.

Ordi J, Bergeron C, Hardisson D, McCluggage WG, Hollema H, Felix A, Soslow RA, Oliva E, Tavassoli FA, Alvarado-Cabrero I, Wells M, Nogales FF.

Histopathology. 2014 Jan;64(2):284-92. doi: 10.1111/his.12249. Epub 2013 Sep 20.

PMID:
24111732
30.

DNA methylation signatures identify biologically distinct thyroid cancer subtypes.

Rodríguez-Rodero S, Fernández AF, Fernández-Morera JL, Castro-Santos P, Bayon GF, Ferrero C, Urdinguio RG, Gonzalez-Marquez R, Suarez C, Fernández-Vega I, Fresno Forcelledo MF, Martínez-Camblor P, Mancikova V, Castelblanco E, Perez M, Marrón PI, Mendiola M, Hardisson D, Santisteban P, Riesco-Eizaguirre G, Matías-Guiu X, Carnero A, Robledo M, Delgado-Álvarez E, Menéndez-Torre E, Fraga MF.

J Clin Endocrinol Metab. 2013 Jul;98(7):2811-21. doi: 10.1210/jc.2012-3566. Epub 2013 May 10.

PMID:
23666970
31.

mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study.

Bernet L, Martinez Benaclocha M, Castera C, Cano Muñoz R, Sevilla F, Alba J, de Dios Barranco J, Cordoba A, Garcia-Caballero T, Hardisson D, de Francisco Hernandez JM, Lazaro JM, Polo L, Riu F, Rezola R, Rojo F, Ruiz I, Hernándiz A, de la Cámara de Las Heras JM, Coupe VM.

Diagn Mol Pathol. 2012 Jun;21(2):84-92. doi: 10.1097/PDM.0b013e3182360b0a.

PMID:
22555091
32.

Comparison of molecular analysis and histopathology for axillary lymph node staging in primary breast cancer: results of the B-CLOSER-I study.

Vegué LB, Rojo F, Hardisson D, Iturriagagoitia AC, Panadés MJ, Velasco A, Bonet EL, Muñoz RC, Polo L; B-CLOSER-I Investigators.

Diagn Mol Pathol. 2012 Jun;21(2):69-76. doi: 10.1097/PDM.0b013e318241117b.

PMID:
22555089
33.

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation.

Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Court W, Lomas C, Mendiola M, Hardisson D, Eccles SA.

BMC Biol. 2012 Mar 22;10:29. doi: 10.1186/1741-7007-10-29.

34.

Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas.

Moreno-Bueno G, Salvador F, Martín A, Floristán A, Cuevas EP, Santos V, Montes A, Morales S, Castilla MA, Rojo-Sebastián A, Martínez A, Hardisson D, Csiszar K, Portillo F, Peinado H, Palacios J, Cano A.

EMBO Mol Med. 2011 Sep;3(9):528-44. doi: 10.1002/emmm.201100156. Epub 2011 Jul 6.

35.

From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer.

Gómez-Raposo C, Mendiola M, Barriuso J, Hardisson D, Redondo A.

Expert Opin Investig Drugs. 2011 May;20(5):591-4. doi: 10.1517/13543784.2011.571202.

PMID:
21452927
36.

Aurora B kinase expression in laryngeal squamous cell carcinoma and its prognostic implications.

García-Fernández E, De Diego JI, Collantes-Bellido E, Mendiola M, Prim MP, Pérez-Fernández E, Miguel-Martín M, Nistal M, Hardisson D.

Histopathology. 2011 Feb;58(3):368-76. doi: 10.1111/j.1365-2559.2011.03757.x. Epub 2011 Feb 7.

PMID:
21299608
37.

A method to calculate the volume of palatine tonsils.

Prim MP, De Diego JI, García-Bermúdez C, Pérez-Fernández E, Hardisson D.

Anat Rec (Hoboken). 2010 Dec;293(12):2144-6. doi: 10.1002/ar.21278.

38.

The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.

Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D, Rodríguez-Antona C.

Endocr Relat Cancer. 2010 Dec 21;18(1):85-95. doi: 10.1677/ERC-10-0148. Print 2011 Feb.

39.

Histopathological analysis of human specimens removed from the injection area of expanded adipose-derived stem cells.

García-Arranz M, Gómez-Pinedo U, Hardisson D, Herreros D, Guadalajara H, García-Gómez I, García-Verdugo JM, García-Olmo D.

Histopathology. 2010 Jun;56(7):979-82. doi: 10.1111/j.1365-2559.2010.03573.x. No abstract available.

PMID:
20636801
40.

An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer.

Sánchez-Navarro I, Gámez-Pozo A, Pinto A, Hardisson D, Madero R, López R, San José B, Zamora P, Redondo A, Feliu J, Cejas P, González Barón M, Angel Fresno Vara J, Espinosa E.

BMC Cancer. 2010 Jun 28;10:336. doi: 10.1186/1471-2407-10-336.

41.

Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues.

Sánchez-Navarro I, Gámez-Pozo A, González-Barón M, Pinto-Marín A, Hardisson D, López R, Madero R, Cejas P, Mendiola M, Espinosa E, Vara JA.

Biotechniques. 2010 May;48(5):389-97. doi: 10.2144/000113388.

42.

Molecular characterization of ovarian cancer by gene-expression profiling.

Gómez-Raposo C, Mendiola M, Barriuso J, Hardisson D, Redondo A.

Gynecol Oncol. 2010 Jul;118(1):88-92. doi: 10.1016/j.ygyno.2010.03.012. Epub 2010 May 1. Review.

PMID:
20439111
43.

Angiogenesis and ovarian cancer.

Gómez-Raposo C, Mendiola M, Barriuso J, Casado E, Hardisson D, Redondo A.

Clin Transl Oncol. 2009 Sep;11(9):564-71. Review.

PMID:
19775995
44.

Comparison of prognostic gene profiles using qRT-PCR in paraffin samples: a retrospective study in patients with early breast cancer.

Espinosa E, Sánchez-Navarro I, Gámez-Pozo A, Marin AP, Hardisson D, Madero R, Redondo A, Zamora P, San José Valiente B, Mendiola M, González Barón M, Fresno Vara JA.

PLoS One. 2009 Jun 15;4(6):e5911. doi: 10.1371/journal.pone.0005911.

45.

Tiling path genomic profiling of grade 3 invasive ductal breast cancers.

Natrajan R, Lambros MB, Rodríguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchió C, Vatcheva R, Rayter S, Mahler-Araujo B, Fulford LG, Hungermann D, Mackay A, Grigoriadis A, Fenwick K, Tamber N, Hardisson D, Tutt A, Palacios J, Lord CJ, Buerger H, Ashworth A, Reis-Filho JS.

Clin Cancer Res. 2009 Apr 15;15(8):2711-22. doi: 10.1158/1078-0432.CCR-08-1878. Epub 2009 Mar 24.

46.

Aurora kinases as prognostic biomarkers in ovarian carcinoma.

Mendiola M, Barriuso J, Mariño-Enríquez A, Redondo A, Domínguez-Cáceres A, Hernández-Cortés G, Pérez-Fernández E, Sánchez-Navarro I, Vara JA, Suárez A, Espinosa E, González-Barón M, Palacios J, Hardisson D.

Hum Pathol. 2009 May;40(5):631-8. doi: 10.1016/j.humpath.2008.10.011. Epub 2009 Jan 20.

PMID:
19157502
47.

Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma.

Mendiola M, Barriuso J, Redondo A, Mariño-Enríquez A, Madero R, Espinosa E, Vara JA, Sánchez-Navarro I, Hernández-Cortes G, Zamora P, Pérez-Fernández E, Miguel-Martín M, Suárez A, Palacios J, González-Barón M, Hardisson D.

PLoS One. 2008;3(12):e4051. doi: 10.1371/journal.pone.0004051. Epub 2008 Dec 29.

48.

Signet-ring stromal tumor of the ovary: report of a case and review of the literature.

Hardisson D, Regojo RM, Mariño-Enríquez A, Martínez-García M.

Pathol Oncol Res. 2008 Sep;14(3):333-6. doi: 10.1007/s12253-008-9080-6. Epub 2008 Aug 29. Review.

PMID:
18758997
49.

Transitional cell carcinoma of the endometrium and endometrial carcinoma with transitional cell differentiation: a clinicopathologic study of 5 cases and review of the literature.

Mariño-Enríquez A, González-Rocha T, Burgos E, Stolnicu S, Mendiola M, Nogales FF, Hardisson D.

Hum Pathol. 2008 Nov;39(11):1606-13. doi: 10.1016/j.humpath.2008.03.005. Epub 2008 Jul 11. Review.

PMID:
18620731
50.

Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas.

Peinado H, Moreno-Bueno G, Hardisson D, Pérez-Gómez E, Santos V, Mendiola M, de Diego JI, Nistal M, Quintanilla M, Portillo F, Cano A.

Cancer Res. 2008 Jun 15;68(12):4541-50. doi: 10.1158/0008-5472.CAN-07-6345.

Supplemental Content

Loading ...
Support Center